Generic Mutamycin launch grows Mylan's oncology portfolio
Mylan recently introduced its generic Mutamycin (mitomycin for injection). The product, indicated to treat stomach and pancreatic cancers in combination with other medicines, grows Mylan's injectable and oncology portfolios, the Pittsburgh-based company said.
Mylan's generic Mutamycin will be available in 5- 20- and 40-mg/vial single-dose vial. The company had previously received Food and Drug Administration approval for the product, which had U.S. sales of roughly $59 million for the 12 months ended January 2018, according to IQVIA data.
Mylan's generic Mutamycin will be available in 5- 20- and 40-mg/vial single-dose vial. The company had previously received Food and Drug Administration approval for the product, which had U.S. sales of roughly $59 million for the 12 months ended January 2018, according to IQVIA data.